Cryo-Cell International (Cryo-Cell International) Risk Assessment

View and export this data going back to . Start your Free Trial

What is Cryo-Cell International Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cryo-Cell International is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Cryo-Cell International's Risk Assessment

For the Medical Care Facilities subindustry, Cryo-Cell International's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryo-Cell International's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Risk Assessment falls into.

Cryo-Cell International (AMEX:CCEL) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cryo-Cell International Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryo-Cell International (Cryo-Cell International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ZCY:Germany

Address

700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677

Website

https://www.cryo-cell.com

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.

Executives

David Portnoy	director, officer: Co-Chief Executive Officer	C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy	director	415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy	director, officer: Co-Chief Executive Officer	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg	10 percent owner	455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust	10 percent owner	455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans	officer: VP, Finance, CFO
Oleg Mikulinsky	officer: Chief Information Officer	700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala	director	700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian	director
Sung Won Sohn	director	700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho	director	C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250